monoamine

(redirected from monoamines)
Also found in: Dictionary, Thesaurus, Medical.

monoamine

[¦män·ō′am‚ēn]
(organic chemistry)
An amine compound that has only one amino group.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Organophilic Modification of the Layered Silicates by Low-Molecular and Polymeric Monoamines, Diamines, and Triamines
For this purpose, we evaluated locomotor activity across the course of exposure, whereas monoamine levels in striatum, prefrontal cortex, nucleus accumbens, and hypothalamus and stereologic cell counts of TH-positive (T[H.sup.+]) and TH-negative (T[H.sup.-]) cells in the midbrain were evaluated 2 weeks after cessation of exposure.
Pharmacologic treatments for depression have advanced greatly since the development of the first therapies, monoamine oxidase inhibitors (MAOIs).
Current pharmacotherapy is based on the monoamine hypothesis, which holds that depression is the result of depressed levels of certain substances--classified as monoamines--in the brain.
Exposure to styrene in rats produced a significant increase in brain 5-HT and caused a significant decrease in monoamine oxidase (MAO) activity (Husain, Srivastava, Mushtaq, & Seth, 1980).
2(A) and (B) depicts the effect of OS compounds on CUS-induced alterations in the monoamine and metabolite levels in the frontal cortex.
The researchers then looked at the polymorphisms in genes that coded for two enzymes that regulate monoamine levels: catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAO-A).
The influences of restraint stress on the levels of monoamines: noradrenaline (NE), dopamine (DA) and serotonin (5-HT) in cerebral cortex, as well as plasma corticosterone (CORT) were studied in mice.
In psychiatry, there are several examples, including chlorpromazine for psychosis and monoamine oxidase inhibitors and tricyclics for depression.
The ratios of metabolites to monoamines were evaluated to estimate the activity of brain monoamine metabolism.
Pharmaceutical company Neurocrine Biosciences (NasdaqGS:NBIX) revealed on Thursday the receipt of the US Food and Drug Administration's (FDA) Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in treating tardive dyskinesia.
Combination therapies for major depressive disorder (MDD) may enhance antidepressant efficacy and long-term results by working synergistically to regulate monoamines availability.